• Growing Adoption of AI-Driven Precision Cardiovascular Medicine Tests Spans Concierge, Functional Medicine, and Primary Care Practices

CHICAGO / Oct 21, 2025 / Business Wire / Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven Precision Cardiovascular Medicine company, today announced the Company has partnered with 15 new provider organizations across the United States. This expansion demonstrates the continued adoption of the Company's innovative blood tests, Epi+Gen CHD™ and PrecisionCHD™, which are transforming the prevention, detection, and management of coronary heart disease across diverse clinical settings.

The new provider organizations represent various medical specialties and care models, spanning four major regions:

Northeast

• An integrative cardiology practice in Pennsylvania that combines conventional cardiology with complementary approaches to treat the whole person, emphasizing prevention and lifestyle modification alongside traditional cardiac care.
• A concierge medicine practice in Maryland offering personalized care with enhanced access and comprehensive health management for patients seeking a more individualized healthcare experience.
• A concierge primary care practice in Delaware focused on building a patient-centered practice with direct access to care and personalized attention.

South

• Two concierge medicine practices in Florida, both emphasizing personalized, attentive care with same-day or next-day appointments, longer visit times, and comprehensive health management. These practices focus on preventive medicine and building strong physician-patient relationships.
• A concierge internal medicine practice in Texas dedicated to providing individualized care with a focus on prevention, wellness, and managing complex medical conditions through enhanced physician availability and personalized treatment approaches.

Midwest

• A functional medicine and holistic care practice in Illinois that addresses the root causes of disease through an integrative approach, combining conventional and alternative therapies to optimize patient health.
• A longevity and concierge medicine practice in Wisconsin focused on extending healthspan through advanced diagnostics, preventive strategies, and personalized interventions designed to help patients live longer, healthier lives.
• A functional medicine practice in Ohio specializing in identifying and treating the underlying causes of chronic health conditions through comprehensive testing and personalized treatment protocols.
• A concierge primary care practice in Indiana committed to personalized care, offering comprehensive preventive medicine and a superior healthcare experience to patients.
• A newly opened primary care practice in Illinois led by a physician committed to delivering comprehensive, patient-centered primary care with a focus on building lasting relationships with patients.

West

• A concierge medicine practice in California providing personalized, comprehensive healthcare with enhanced physician access and individualized treatment plans tailored to each patient's unique needs.
• Two concierge medicine practices in Oregon, both dedicated to providing accessible, personalized care with a focus on prevention, wellness, and treating the whole patient through longer appointments and direct physician communication.
• A direct primary care practice in Washington State offering membership-based healthcare that eliminates insurance barriers, providing patients with affordable, accessible, and personalized primary care services.

By integrating Epi+Gen CHD™ and PrecisionCHD™ into their practices, these providers can leverage the Company's advanced integrated epigenetic-genetic testing technology to obtain actionable insights into coronary heart disease, heart attack risk, and help guide personalized treatment plans for their patients. These solutions address the rising prevalence of cardiovascular disease across various patient demographics and care settings.

The addition of these 15 new provider partners is a significant milestone in Cardio Diagnostics' mission to make Precision Cardiovascular Medicine more accessible. As providers across the country increasingly adopt evidence-based approaches to helping their patients maintain cardiovascular health, the Company's innovative tests are becoming essential tools for more effective heart health management.

"This expansion reflects the strong momentum we're building in the provider community," said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. "These partnerships span an impressive range of care models, from concierge and functional medicine to direct primary care, which demonstrates that providers across the healthcare spectrum recognize the value of our precision approach. By equipping these practices with our Epi+Gen CHD™ and PrecisionCHD™ tests, we're not only enhancing patient care and driving better outcomes, but we're also making Precision Cardiovascular Medicine accessible to more patients nationwide."

Cardio Diagnostics' solutions uniquely combine epigenetics, genetics, and AI to provide deep insights into heart attack risk, and the presence of coronary heart disease and their drivers. With coronary heart disease remaining the leading cause of death globally, these tools are crucial for both early detection and ongoing management across diverse patient populations and healthcare settings.

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ("Core Technology") for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/.

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, and dependence on results as discussed in the Annual Report on Form 10-K for the period ended December 31, 2024, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.